key: cord-0743145-0pqexn33
authors: Rane, Madhura S; Kochhar, Shivani; Poehlein, Emily; You, William; Robertson, Mc Kaylee M; Zimba, Rebecca; Westmoreland, Drew A; Romo, Matthew L; Kulkarni, Sarah G; Chang, Mindy; Berry, Amanda; Parcesepe, Angela M; Maroko, Andrew R; Grov, Christian; Nash, Denis; CHASING COVID Cohort Study Team, for the
title: Determinants and trends of COVID-19 vaccine hesitancy and vaccine uptake in a national cohort of U.S. adults: A longitudinal study
date: 2022-01-05
journal: Am J Epidemiol
DOI: 10.1093/aje/kwab293
sha: dbfbca4a28f4ab9fa2fb9bd942b6ad123e13e359
doc_id: 743145
cord_uid: 0pqexn33

We estimated the trends and correlates of vaccine hesitancy, and its association with subsequent vaccine uptake among 5,458 adults in the United States. Participants belonged to the CHASING COVID Cohort, a national longitudinal study. Trends and correlates of vaccine hesitancy were examined longitudinally in eight interview rounds from October 2020 to July 2021. We also estimated the association between willingness to vaccinate and subsequent vaccine uptake through July 2021. Vaccine delay and refusal decreased from 51% and 8% in October 2020 to 8% and 6% in July 2021, respectively. Compared to Non-Hispanic (NH) White participants, NH Black and Hispanic participants had higher adjusted odds ratios (aOR) for both vaccine delay (aOR: 2.0 [95% CI: 1.5, 2.7] for NH Black and 1.3 [95% CI: 1.0, 1.7] for Hispanic) and vaccine refusal (aOR: 2.5 [95% CI: 1.8, 3.6] for NH Black and 1.4 [95% CI: 1.0, 2.0] for Hispanic) in June 2021. COVID-19 vaccine hesitancy was associated with lower odds of subsequent vaccine uptake (aOR: 0.15, 95% CI: 0.13, 0.18 for vaccine-delayers and aOR: 0.02; 95% CI: 0.01, 0.03 for vaccine-refusers compared to vaccine-willing participants), adjusted for sociodemographic factors and COVID-19 history. Vaccination awareness and distribution efforts should focus on vaccine delayers.

Vaccination awareness and distribution efforts should focus on vaccine delayers.

As the coronavirus disease-19 (COVID-19) pandemic continues to be a health crisis globally, widespread vaccination is the most effective and sustainable long-term mitigation strategy. demand for coronavirus vaccines has decreased in recent months (5, 6) . As vaccine eligibility criteria expands, we would expect dramatic reductions in COVID-19 incidence, hospitalizations, and mortality in all age groups as vaccine uptake increases (7) .

For the COVID-19 vaccination program to be as impactful as possible, large numbers of people must be vaccinated quickly while also ensuring equity in access and uptake. Low vaccine acceptance and lack of easy access to vaccinations can be barriers to achieving both high and equitable vaccination coverage (8) . This could create vaccination cold-spots where periodic disease outbreaks can still occur (9) and vaccine-resistant strains might evolve (10) .

While anti-vaccine sentiment remains a threat to COVID-19 vaccine uptake in the U.S., other factors, such as political mistrust, lack of assurance about safety and efficacy, and a lack of clear public health messaging may have influenced vaccine hesitancy specifically for coronavirus vaccines (11) . The rapid production of COVID-19 vaccines in less than a year may have engendered concerns among the public, considering the average vaccine development timeline spans around ten years (12) . According to a Kaiser Family Foundation poll from August 2020, a majority (62%) of respondents believed that socio-political factors and pressures could lead to a rushed approval for the COVID-19 vaccine without assurances vaccine if approved before the U.S presidential elections in November 2020 (13) . Based on a systematic review of surveys conducted between April and October 2020, the U.S. recorded lower intention to vaccinate against COVID-19 (ranging from 38-49% across regions) compared to other high-income countries such as Denmark (80%) and the United Kingdom (79%) (14) .

Understanding COVID-19 vaccine hesitancy and addressing it promptly is essential for a successful and equitable vaccine roll-out. In this study, we aimed to 1) measure trends in vaccine hesitancy in the U.S. for adults; 2) identify subpopulations that might be less willing to be vaccinated; 3) examine sociodemographic and behavioral factors as well as COVIDrelated risk perceptions that correlate with vaccine hesitancy; and finally, 4) assess the association between vaccine hesitancy and subsequent vaccine uptake.

This study used data from the Communities, Households, and SARS-CoV-2 Epidemiology (CHASING) COVID Cohort study. CHASING COVID is a national prospective cohort study in the U.S. launched on March 28, 2020, to understand the spread and impact of the SARS-CoV-2 pandemic within households and communities. Details of survey methodology are described elsewhere (15) . Briefly, study participants were recruited through social media platforms or through referrals using advertisements that were in both English and Spanish. were administered to capture COVID-19 outcomes and vaccine uptake. For this study, we included participants who responded to at least one interview round starting October 2020

[V3].

The study was approved by the Institutional Review Board at the City University of New York (CUNY).

Vaccine hesitancy between October 2020 and June 2021

Using seven rounds of visits from October 2020 -June 2021, we assessed participants' willingness to vaccinate with the question "If a coronavirus vaccine became available would you: a) Immediately get the vaccine; b) Delay getting the vaccine; c) Never get the vaccine."

Those who responded that they would "Delay getting vaccine" were categorized as vaccine delayers and those who responded that they would "Never get the vaccine" as vaccine refusers. COVID-19 vaccine delayers and refusers are together termed as COVID-19 vaccine hesitant, based on the WHO Strategic Advisory Group of Experts on Immunization (SAGE) definition of the term "vaccine hesitancy" (16) . The outcome, "COVID-19 vaccine

hesitancy," was defined with three levels: vaccinate immediately, delay vaccine, and refuse vaccine. "Vaccinate immediately" was the reference category in statistical models.

Participants who reported receiving the vaccine in a given interview were not asked about willingness to vaccinate again in subsequent interviews. We imputed their vaccine willingness status as "vaccinate immediately" for subsequent interviews assuming that if they received the vaccine, they were willing to get it immediately.

Since the vaccine became available to healthcare workers and high-risk individuals, in

December 2020, we queried vaccination uptake ("Have you been vaccinated against COVID-19 with a Food and Drug Administration (FDA) approved vaccine/not in a vaccine trial: a) Yes; b) No; c) Don't know/Not sure") in all interview rounds starting December 2020. We also asked about vaccine-related side effects, motivation for getting vaccinated, and reasons for delay. Vaccine uptake through July 2021 was coded dichotomously (yes/no).

Participants' age, race/ethnicity, income, education, and essential worker and healthcare worker status were determined at enrollment (V0, V1). Essential worker and healthcare worker status was asked again in October 2020 and the most recent reported status was used in the models. Self-reported race/ethnicity was coded based on standardized Office of Management and Budget categories (17) .

To assess the association between prior exposure to COVID-19 and vaccine hesitancy, we defined COVID-19 history as a dichotomous variable using three inputs: self-reported

COVID-19 PCR diagnosis or seropositivity (visits V0-V7), self-identifying as a COVID-19

long-hauler (visits V4-V7) or being seropositive for COVID-19 antibodies in two rounds of testing performed as part of our study from May-September 2020 and from November 2020-January 2021. To measure COVID-19 risk perception, we asked participants if they were worried that they would get sick from coronavirus, that their loved ones would get sick from coronavirus, and that coronavirus will overwhelm hospitals (not at all worried/ not too worried/ somewhat worried /very worried). COVID-19 related anxiety was measured using the Generalized Anxiety Disorder-7 (GAD-7) scale, and participants were categorized as having "no/low anxiety" or "moderate/high anxiety" based on their median scores (visits V0-V7). We also asked if they felt that the federal government was prioritizing the safety of citizens during the pandemic (agree/disagree/neutral) (V6).

To understand if vaccine hesitancy was correlated with the use of NPIs, we drew on participants' responses to questions about their mask use and social distancing in public places in the June 2021 interview (V7) (Specific questions in Table 1 ). We assigned a score of 1 for responses that indicated lack of participant engagement with individual NPIs and 0 otherwise. We summed the coded behaviors to create a risk score. Participants engaging in 5 or more risk-taking activities (median risk score=5) were defined as engaged in higher risk behavior. We separately assessed whether most recent masking behavior and air travel were associated with vaccine hesitancy in June 2021.

Chi-squared tests and corresponding P values were used to describe the distribution of patient (18) .

Multinomial generalized estimating equation (GEE) models were used to measure changes in vaccine hesitancy over time between October 2020 and July 2021 by estimating odds ratios (aORs) and 95% confidence intervals (CIs), adjusted for age, gender, race/ethnicity, and comorbidities. We included an interaction term between race/ethnicity and calendar time of interview in the model to test the hypothesis that the rate of change of vaccine hesitancy differed by race/ethnicity as found in some studies (19) . Longitudinal correlation between participants was specified using an independence correlation matrix and variance was estimated using robust variance estimators.

Factors associated with vaccine hesitancy were assessed from the June 2021 interview (V7) using multinomial logistic regression to estimate ORs and 95% CIs. Separate models were built to assess the association between sociodemographic factors, COVID-19 history, behavioral characteristics, and COVID-19 risk perception and vaccine hesitancy. Models for COVID-19 history, behavioral characteristics, and COVID-19 risk perception were adjusted for sociodemographic factors that were statistically significantly associated with the outcome (2-sided P <0.05).

Association between vaccine hesitancy and subsequent vaccine uptake was assessed using logistic regression models, which estimated ORs and 95% CIs. For those who received the

vaccine, association with vaccine hesitancy was assessed using the most recent visit prior to the one when vaccine receipt was reported. Similarly, for those who remained unvaccinated as of July 2021, we used vaccine hesitancy status reported in the June 2021 visit (or prior if missing), to ensure exposure measurement in both groups is comparable. The model was adjusted for sociodemographic characteristics, comorbidities, and COVID-19 history.

A total of 5,458 participants responded to at least one of the interview rounds between

October 2020 and July 2021, of which 4,191 (76%) completed all full interview rounds.

Vaccination status was obtained for all study participants and only one participant was missing vaccine willingness status across all visits. Vaccine delay decreased significantly from 51.0% to 6.7% between October 2020 to July 2021 (Web Table 1 ). Decrease in vaccine refusal was also statistically significant but less prominent (8.4% to 5.7%). We illustrated changes in vaccine hesitancy among participants using a Sankey plot (Web Figure 1 ). Most participants moved from the "delay" vaccine category to the "immediately" vaccinate category and eventually to the "vaccinated" category. Movement out of the "never" vaccinate category to "delay" or "immediately" vaccinate categories was limited.

Of the cohort participants who responded to the most recent full interview (June 2021, n=4,571), 85.3% said they would immediately get the vaccine/were already vaccinated, 8.8%

were vaccine delayers, and 5.9% were vaccine refusers ( 

Overall, vaccine delay decreased by 96% (aOR: 0.04, 95% CI: 0.03, 0.05) and vaccine refusal by 71% (aOR: 0.29, 95% CI: 0.24, 0.35) between October 2020 and July 2021, adjusted for race/ethnicity, age, gender, and comorbidities (Table 2) . Even though vaccine hesitancy decreased overall, the rate of change differed by race/ethnicity. In December relative to

October 2020, NH Black participants had 2.8 times (95% CI: 2.2, 3.6) higher odds of delaying vaccine compared to NH Whites, adjusted for age, gender and comorbidities ( Figure   1A ). In July 2021 relative to October 2020, NH Black participants still had significantly higher odds of delaying COVID-19 vaccine than NH Whites (aOR:1.7; 95% CI: 1.2, 2.5).

Similar trends in vaccine delay were seen for Hispanic compared to NH White participants.

In December compared to October 2020, adjusted odds of vaccine refusal in NH Black participants were 1.6 times greater (95% CI: 1.2, 2.2) compared to NH Whites. However, by

July 2021 compared to October 2020, vaccine refusal in NH Black participants was significantly lower than in NH Whites (aOR: 0.6, 95% CI: 0.4, 0.8), adjusted for age, gender and comorbidities. ( Figure 1B ).

Sociodemographics. Table 2 ).

Behaviors. Participants who reported wearing a mask in the prior month had substantially lower odds of vaccine refusal (aOR: 0.42, 95% CI: 0.31, 0.58) (Web Table 2 (44) (45) (46) . Cohort participants who were less likely to engage in protective behavior such as mask-wearing and social distancing were also less willing to be vaccinated. This may be due to lack of trust in authorities as source of COVID-19 information (47) The strengths of our study include prospective assessment of association between willingness to vaccinate and subsequent vaccine uptake, a diverse and geographically representative cohort, and detailed data on demographics, biomarkers on prior COVID-19 exposures, and behavioral characteristics that are not available in surveillance databases, electronic medical records, or cross-sectional surveys/polls. Our prospective design with repeat measurements allowed us to assess how individual-level vaccine hesitancy has changed over the course of the pandemic as vaccines became more widely available.

Our study also has limitations. Participants self-reported vaccination status as well as exposures, so the study is subject to misclassification and reporting bias. Because enrollment was done online, those without smartphones, computers, or a stable internet connection were less likely to be included. This is not a population-based sample as participants had to opt into the study. While we adjusted all models for demographic factors, there is a possibility of unmeasured and/or uncontrolled confounding. Not all participants responded to all interview rounds, although visit-level missingness was not associated with vaccination status. However, missingness was associated with age, sex, college education, serostatus, and COVID-19

history, which could potentially bias our results.

In summary, the proportion of COVID-19 vaccine delayers decreased substantially from

October 2020 to July 2021 as vaccine availability increased. However, a small fraction Thanks: We thank Dr. Patrick Sullivan and MTL labs for local validation work on the serologic assays for use with dried blood spots that greatly benefited our study. We are also grateful to MTL Labs for processing specimen collection kits and serologic testing of our cohort's specimens. 

WHO Director-General's opening remarks at the media briefing on

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

COVID-19 Vaccinations in the United States

COVID Data Tracker: Trends in Number of COVID-19 Vaccinations in the US

tracker/#vaccination-trends_vacctrends-onedose-cum)

The impact of vaccination on COVID-19 outbreaks in the United States

Planning for a COVID-19 Vaccination Program

Association between vaccine refusal and vaccine-preventable diseases in the United States A review of measles and pertussis

Covid: new vaccines needed globally within a year, say scientists. The Guardian

COVID-19 Vaccination Hesitancy in the United States: A Rapid National Assessment

COVID-19 vaccine development pipeline gears up

Poll: Most Americans Worry Political Pressure Will Lead to Premature Approval of a COVID-19 Vaccine; Half Say They Would Not Get a Free Vaccine Approved Before Election Day

Confidence and Receptivity for COVID-19 Vaccines: A Rapid Systematic Review

Cohort profile: a national, communitybased prospective cohort study of SARS-CoV-2 pandemic outcomes in the USA-the CHASING COVID Cohort study

Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants

Office of Information and Regulatory Affairs. Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity

Feed-Forward Neural Networks and Multinomial Log-Linear Models

COVID-19 vaccine hesitancy in underserved communities of North Carolina

COVID-19 vaccine hesitancy and resistance: Correlates in a nationally representative longitudinal survey of the Australian population

Psychological characteristics associated with COVID-19 vaccine hesitancy and resistance in Ireland and the United Kingdom

Attitudes toward a potential SARS-CoV-2 vaccine : A survey of U.s. adults: A survey of U.s. adults

COVID-19 vaccine acceptability and inequity in the United States: Results from a nationally representative survey

Determinants of COVID-19 vaccine acceptance in the US

Hospitalization and Mortality among Black Patients and White Patients with Covid-19

Disparities in COVID-19 Testing

COVID-19 and African Americans

Understanding Drivers of COVID-19

Vaccine Hesitancy Among Blacks

A New Campaign By Black Health Care Workers for Black People about the COVID-19 Vaccines

Addressing racial/ethnic disparities in the COVID-19 vaccination campaign

Assessment of Racial and Ethnic Disparities in Access to COVID-19 Vaccination Sites in

Labor force characteristics by race and ethnicity

Preferences for COVID-19 vaccine distribution strategies in the US: A discrete choice survey

Interim Guidance on Duration of Isolation and Precautions for Adults with COVID-19

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Why Vaccines May Be Helping Some With Long COVID

The Impact of COVID Vaccination on Symptoms of Long COVID. An International Survey of People with Lived Experience of Long COVID

Are vaccines safe in patients with Long COVID? A prospective observational study

Unwillingness to engage in behaviors that protect against COVID-19: the role of conspiracy beliefs, trust, and endorsement of complementary and alternative medicine

Behavioral nudges increase COVID-19 vaccinations: Two randomized controlled trials

Communicating about COVID-19 vaccine development and safety

Johnson Vaccinations Paused After Rare Clotting Cases Emerge. The New York Times

Understanding COVID-19 vaccine hesitancy

Effectiveness of COVID-19 Vaccines in

Outdoors 2,110 46